Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Combined With Hydroxychloroquine in High Risk Pregnancies for Preeclampsia
NCT05287321Phase 3Recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine in preeclampsia (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Composite morbidity. Started May 2022; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT05287321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287321.